- Phase 3 largely complete – six positive trials, US application planned for early 2027
- Not yet approved by any regulator – including the FDA and the EU
- Up to about 28–30% weight loss in trials – under medical supervision
- Common side effects: nausea, vomiting, diarrhea, abnormal skin sensations
- Black-market product: cases of acute liver injury documented
What is retatrutide?
Retatrutide (development code LY3437943) is a drug candidate from the US pharmaceutical company Eli Lilly, being developed to treat obesity, type 2 diabetes and related conditions. It is a single molecule that binds to three hormone receptors at the same time: GIP, GLP-1 and glucagon. That's why it is called a "triple agonist". In the trials it is injected under the skin once a week. [1]
For comparison: semaglutide (Wegovy, Ozempic) acts only on the GLP-1 receptor, tirzepatide (Mounjaro, Zepbound) on GIP and GLP-1. Retatrutide also activates the glucagon receptor, which researchers hope will increase energy expenditure and fat loss. The exact mechanisms are not yet fully understood. [2]
What do the studies show?
The weight-loss data are the strongest seen so far for any weight-loss drug. Important: many of the following figures come from the manufacturer's press releases ("topline results"). Some of the full, peer-reviewed publications are still pending. [2]
| Study | Participants | Result (highest dose) |
|---|---|---|
| Phase 2 (NEJM, 2023) | Obesity without diabetes | −24.2% body weight after 48 weeks [3] |
| TRIUMPH-4 (Dec 2025) | Obesity + knee osteoarthritis | −28.7% after 68 weeks [4] |
| TRANSCEND-T2D-1 (Mar 2026) | Type 2 diabetes | −16.8% after 40 weeks [4] |
| TRIUMPH-1 (May 2026) | 2,339 adults with obesity | −17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg) vs. −3.9% placebo after 80 weeks [4] |
| TRIUMPH-2 (Jul 2026) | 1,152 adults with type 2 diabetes | up to −20.8% after 80 weeks, HbA1c down by up to 1.6 points [5] |
| TRIUMPH-3 (Jul 2026) | 1,949 adults with severe obesity + cardiovascular disease | −21.6% (9 mg), −22.6% (12 mg) vs. −3.2% placebo after 80 weeks [5] |
All studies by phase
Eli Lilly has been testing retatrutide in human clinical trials since 2019. Here is an overview of all major studies. The trials are registered on ClinicalTrials.gov; the trial ID (NCT) links directly to the entry.
- Phase 1 (2019–2020) – tolerability and mode of action in healthy people and people with type 2 diabetes.Basis for the phase 2 doses
- Phase 2 obesity (published 2023, New England Journal of Medicine) – up to −24.2% body weight after 48 weeks. [3]Jastreboff AM et al., N Engl J Med 2023;389:514–526
- TRIUMPH-4, phase 3 (December 2025) – obesity with knee osteoarthritis: −28.7% after 68 weeks. [4]Topline result from Lilly
- TRANSCEND-T2D-1, phase 3 (March 2026) – type 2 diabetes: −16.8% after 40 weeks. [4] Published in The Lancet in June 2026. [21]NCT06354660
- TRIUMPH-1, phase 3 (May 2026) – 2,339 adults with obesity: up to −25.0% after 80 weeks; with BMI 35 or higher up to −30.3% after 104 weeks. [4][6]NCT05929066 – completed
- TRIUMPH-2, phase 3 (July 2026) – obesity with type 2 diabetes: up to −20.8% after 80 weeks. [5] Published in The Lancet in September 2026. [21]NCT05929079 – completed
- TRIUMPH-3, phase 3 (July 2026) – severe obesity with cardiovascular disease: up to −22.6% after 80 weeks. [5]NCT05882045 – completed
- TRANSCEND-T2D-2, phase 3 (October 2026) – first head-to-head comparison: retatrutide vs. Ozempic 2 mg in 1,298 adults with type 2 diabetes. Retatrutide lowered HbA1c more and led to more than twice the weight loss (up to −20.9% vs. −9.4%). [20][21]NCT06260722 – sixth positive phase 3 trial
- TRIUMPH-5, phase 3 (ongoing) – head-to-head comparison with tirzepatide in obesity. [22]
- TRIUMPH-Outcomes, phase 3 (ongoing, expected until February 2029) – about 10,000 participants, studying heart and kidney events over about 5 years. [23]NCT06383390
Bottom line: the phase 3 program for approval for weight reduction is largely complete. Lilly says it has reached the data basis for worldwide approval applications. [1] The long-term heart and kidney study, however, will run for years.
In an extension of TRIUMPH-1, participants with severe obesity (BMI 35 or higher) lost an average of 30.3% of their body weight after 104 weeks. [6] For comparison: until now, such numbers were almost only seen with bariatric surgery.
Important context: in all studies, retatrutide was given under medical supervision, using pharmaceutical-grade product and with slow dose escalation over several months – conditions that have nothing in common with the black market.
Side effects from the studies
The side effects resemble those of known weight-loss injections, but some occur more often with retatrutide – especially at the highest dose.
Gastrointestinal symptoms (very common)
In TRIUMPH-1, at the highest dose 42.4% of participants had nausea (placebo: 14.8%), 32.0% diarrhea, 26.1% constipation and 25.3% vomiting (placebo: 4.8%). [4][7] The symptoms mainly occur during the dose-escalation phase.
Abnormal skin sensations (dysesthesia)
A notable finding for retatrutide: about one in ten participants at the highest doses experienced abnormal skin sensations such as tingling, burning or sensitivity to touch. They were mostly mild to moderate and resolved in most people while still on treatment. [6] In TRIUMPH-2 and TRIUMPH-3 the rate was 4.5–7.3% vs. 0.7–1.3% on placebo. [5]
In the head-to-head comparison with Ozempic, abnormal skin sensations occurred in 4.8% and 6.5% (9 mg / 12 mg) vs. 2.7% on Ozempic; discontinuations due to side effects were 4.8% and 7.9% vs. 2.7%. [20]
Urinary and respiratory tract infections
Urinary tract infections were somewhat more common on retatrutide than on placebo, as were upper respiratory tract infections. [2][5]
Heart rate
In the phase 2 study, resting heart rate rose in a dose-dependent way; the increase peaked after a few months and then partially declined. [3] What this means in the long term is still open.
Cardiovascular events: no clarity yet
In TRIUMPH-3 there were 27 major cardiovascular events (cardiovascular death, heart attack, stroke) on retatrutide and 23 on placebo. Statistically, this is evidence of neither harm nor benefit – the numbers are too small. [8] A large study with about 10,000 participants designed to answer exactly this question is expected to run until 2029. [9]
Discontinuations
Due to side effects, 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg) of participants in TRIUMPH-1 stopped treatment, vs. 4.9% on placebo. [4] In TRIUMPH-3 it was up to 13.5%. [5] Experts therefore see tolerability as one of the critical issues. [10]
Open questions
- Muscle and bone mass: with very large weight loss, muscle is lost too. How much that applies to retatrutide and what happens to bone density has not yet been sufficiently published. [10]
- Long-term safety: the longest data cover about two years. Rare side effects often only become visible after approval, once very many people use a drug.
- Known risks of the drug class: the prescribing information of approved GLP-1-based drugs lists, among other things, pancreatitis, gallstones, dehydration with kidney strain from vomiting and diarrhea, and low blood sugar in combination with certain diabetes medications. Whether and to what extent this applies to retatrutide must be shown by the approval review.
- Weight regain after stopping: with existing weight-loss injections, many people regain substantial weight after stopping if diet and exercise were not changed permanently.
Approval: where does retatrutide stand? (as of November 2026)
- Worldwide: retatrutide is not approved by any drug regulator – not in the US, the EU or anywhere else. [21]
- USA: Lilly plans to submit the application to the FDA in the first quarter of 2027, once the manufacturing documentation is complete. [5] The FDA review usually takes about 10–12 months, so approval would realistically come at the end of 2027 or in 2028 at the earliest – and it is not guaranteed. In addition, Lilly and the FDA are in a dispute over whether retatrutide is classified as a biologic or a conventional drug; Lilly has filed an appeal. [24]
- Early access in the US: since August 2026 there has been a narrowly limited program for individual patients who meet strict criteria and cannot take part in a trial. The treating doctor has to apply to Lilly, and both the FDA and an ethics committee must agree. [25] That is not an approval and not open sale.
- EU: there is no approval. An unapproved medicinal product may neither be sold nor advertised in the EU.
- According to the manufacturer: retatrutide is an investigational drug that may not legally be sold or promoted for human use. [1]
- Compounding: according to the FDA, retatrutide may also not be compounded by pharmacies in the US. [11]
- Doping: as an unapproved substance, retatrutide falls under WADA category S0 for tested athletes and is prohibited at all times. [12]
The biggest risk: the black market
Because retatrutide gets so much attention, a large gray market has emerged. Sellers offer powder in vials labeled "for research use only" or "not for human consumption" – a trick to get around drug laws. [13] Nobody knows what is really in these vials: content, purity, amount and sterility are untested. The products may contain contaminants, wrong amounts or entirely different substances. [13] They are promoted mainly via social media and influencers. [19]
The consequences are documented:
- Acute liver injury: in June 2026 the health department of the Australian state of Victoria reported six cases of acute liver injury since January in people who had used an unapproved product labeled "Retatrutide". The authority suspects contamination as the cause and warns that all such products pose a risk. [14] According to the authority, warning signs are unusual fatigue, yellowing of the skin or eyes, abdominal pain, dark urine and unusual bruising. [14]
- Hospitalizations: according to a report by the consumer organization Public Citizen, at least 14 hospitalizations linked to retatrutide are documented in the FDA's adverse event reporting system. Since 2024 the FDA has sent at least 14 warning letters to sellers. [15]
- Warning from Switzerland: the Swiss drug regulator Swissmedic explicitly warns against a "retatrutide injection kit" offered on the black market – the substance is not approved anywhere. [16]
- Case reports in the medical literature: a 2026 medical journal described a patient who had to be hospitalized with persistent, hard-to-treat nausea and vomiting after injecting a product reported to contain retatrutide. [18]
- Manufacturer sues: Eli Lilly is taking legal action against companies selling alleged retatrutide. [17]
On top of that come the risks of self-injection: if you reconstitute powder yourself and inject it, you risk infections and abscesses at the injection site, allergic reactions and dosing errors – and in an emergency, no doctor knows what you took.
What you can do instead
If you have significant obesity and can't manage with diet and exercise alone, there are approved drugs such as semaglutide or tirzepatide. They are tested for quality and safety and are prescribed and monitored by a doctor. Talk to your primary care doctor or an obesity clinic about whether they are an option for you.
For most people with moderate overweight, the most effective and safest route remains unspectacular: a moderate calorie deficit, enough protein, strength training and plenty of everyday movement. Even if you take an approved drug later, you need exactly these foundations to keep your muscle and maintain your weight after stopping.
More on other peptides currently being hyped is on our page Peptides – facts, not hype.
Sources
- Eli Lilly and Company: press release “Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials”, July 23, 2026. investor.lilly.com
- Apotheken Umschau (German): “Effects and side effects of the new weight-loss drug retatrutide”. apotheken-umschau.de
- Jastreboff AM et al.: “Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial”. New England Journal of Medicine 2023; 389: 514–526.
- The Pharmaceutical Journal: “Phase III retatrutide study demonstrates 30% weight loss”, May 2026. pharmaceutical-journal.com
- Eli Lilly and Company: press release on TRIUMPH-2 and TRIUMPH-3, July 23, 2026 (PDF). lilly.gcs-web.com
- Business Today: “Lilly's obesity drug retatrutide helps patients lose up to 30% weight in Phase 3 trial”, May 21, 2026, and The Pharmaceutical Journal (see [4]). businesstoday.in
- Second Nature: “Retatrutide produces up to 30.3% weight loss in Phase 3 trial”, updated November 2026. secondnature.io
- Eli Lilly and Company: news release TRIUMPH-2/-3, July 23, 2026. investor.lilly.com
- Close Concerns: summary of TRIUMPH-4 and the TRIUMPH trial program. closeconcerns.com
- Clinical Trials Arena: “Lilly's ‘triple G’ agonist triumphs in Phase III trial, but AEs unnerve analysts”, May 22, 2026. clinicaltrialsarena.com
- Drug Topics: “Some providers prescribe unapproved retatrutide for weight loss at alarming rate”, June 10, 2026. drugtopics.com
- World Anti-Doping Agency (WADA): Prohibited List 2026, section S0 “Non-Approved Substances”. wada-ama.org
- National Consumers League: “Warning About Self-Injecting ‘Research-Grade’ Synthetic Peptides”. nclnet.org
- Department of Health Victoria (Australia): Health Alert “Toxicity linked to unapproved peptide product labelled Retatrutide”, June 19, 2026. health.vic.gov.au
- Public Citizen: “The Miracle Drug and the Peptide Craze Breaking the FDA”, 2026. citizen.org
- Swissmedic (German): warning about counterfeit and misleading “GLP-1” weight-loss products, August 26, 2025. swissmedic.ch
- Healio: “Eli Lilly files lawsuits against six companies for allegedly selling retatrutide”, August 14, 2026. healio.com
- “Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide”, case report, 2026. PubMed Central. pmc.ncbi.nlm.nih.gov
- Hailu KT et al.: “Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks”. Cureus 2026. PubMed Central. pmc.ncbi.nlm.nih.gov
- Eli Lilly and Company: press release TRANSCEND-T2D-2 (head-to-head vs. Ozempic), October 28, 2026, and Clinical Trials Arena: “Lilly's retatrutide beats Ozempic in head-to-head trial”. investor.lilly.com · clinicaltrialsarena.com
- BioPharm International: “Lilly's Retatrutide Doubles Ozempic's Weight Loss in First Phase 3 Head-to-Head Trial”, October 29, 2026 (with references to the Lancet publications of TRANSCEND-T2D-1 and TRIUMPH-2). biopharminternational.com
- AJMC: “Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial”, October 28, 2026. ajmc.com
- ClinicalTrials.gov: TRIUMPH-Outcomes (NCT06383390). clinicaltrials.gov
- AJMC: “5 Things to Know About Retatrutide, the Trillion-Dollar Drug”, August 14, 2026. ajmc.com
- AJMC: “Lilly Expands Retatrutide Access Amid Doctor Pushback”, August 5, 2026. ajmc.com
Information as of November 2026. The research and approval situation is changing constantly. Information only – not a recommendation, not advice on use or treatment and not medical advice. Content is reproduced in summary from the sources cited. We accept no liability for the accuracy, completeness or timeliness of the content or for decisions made on the basis of it; the original source is authoritative.
Your plan – calculated automatically
Calorie needs, a meal plan built from your favorite foods and a training plan for gym, home or hotel – in the 20-week program to become a high performer. Start free, no payment details.
Create a free accountThis article is for general information and does not replace medical advice, diagnosis or treatment. If you have pre-existing conditions, symptoms or take medication, talk to your doctor before changing your diet or training. Information only – not a recommendation, not advice on use or treatment and not medical advice. Content is reproduced in summary from the sources cited. We accept no liability for the accuracy, completeness or timeliness of the content or for decisions made on the basis of it; the original source is authoritative.